We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Tir7.8
Tirzepatide Research
Mostly mechanism / observational
90 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Tirzepatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2026 with a typical study size of 1,879 participants.
Based on 90 studies · 32 meta-analyses · 48 RCTs · 429,866 total participants
Confidence
High confidence
By outcome
Weight managementMean weight reductions up to ~21% over 72 weeks in obesity trials — the largest of any approved weight-loss drug to date, superior to semaglutide head-to-head · Months (dose-escalated over ~20 weeks)
Mostly mechanism / observational61 studies
Glycemic & metabolic controlLowers HbA1c by roughly 1.9-2.6 percentage points in phase-3 diabetes trials; superior to basal insulin and semaglutide 1 mg head-to-head · Weeks to months · Combined large weight loss and strong glycemic control improve overall metabolic status · Months
Mostly mechanism / observational40 studies
Safety profile
Mostly mechanism / observational15 studies
Heart & blood pressure
Mostly mechanism / observational14 studies
Sleep apnea & respiratory
Too few graded studies2 studies
Active research area
90 studies in the last 5 years · Latest meta-analysis: 2026
20212026
1Meta-Analysisn=7,111 · very large study2025
Franco JV, Guo Y, Varela LB, Aqra Z, Alhalahla M, Medina Rodriguez M, Salvador Oscco EL, Patiño Araujo B, Banda S, Escobar Liquitay CM, Bracchiglione J, Meza N, Madrid E. · The Cochrane database of systematic reviews (2025)
Tirzepatide may result in an increase in non-serious adverse events (RR 1.33, 95% CI 1.03 to 1.71; 5 studies, 4582 participants; low-certainty evidence).
The evidence is very uncertain about the effect on serious adverse events (RR 0.99, 95% CI 0.88 to 1.12; 8 studies, 6359 participants; very low-certainty evidence).
Tirzepatide may result in little to no difference in adverse events leading to withdrawal (RR 2.06, 95% CI 1.21 to 3.52; 8 studies, 6359 participants; low-certainty evidence).
In plain English: Further prospective trials are needed to clarify causal mechanisms and inform clinical decision-making.
Liang CS et al. · International journal of molecular sciences (2026)
Odds ratios (ORs) with 95% credible intervals (CrIs) were calculated, and surface under the cumulative ranking curves (SUCRA) were used to estimate relative safety rankings.
Only high-dose tirzepatide (10-15 mg/week) was associated with a significantly increased risk of AKI compared to controls (absolute risk difference: 0.28%; number needed to harm: 357).
In plain English: Precision remains limited; clinicians should maintain vigilance, optimise modifiable risks, individualise dosing, and contribute to post-marketing surveillance.
Benny O, Agarwal A, Alecock H, Subramani RG, Pawar A, Shams Z, Kermansaravi M, Pouwels S, Yang W, Obi CG, Cripps P, Tang A, Gelber E, Lala A, Nadi K, Mahmoud A, Hammoda M, Al-Sarireh H, Egan R, Hanratty D, Drummond A, Caplin S, Harris D, Barry J, Beamish A, Al-Ardah M, Al-Sarireh B, Sum Ong SC, Hajibandeh S, Honey JR, Dababneh A, Ribordy V, Hautz WE, Jakob D, Patel B, Sprackling I, Ashabi A, Kambal A, Oviedo RJ, Parmar C, Mowbray N, Al Hadad M, Gawdat K, Hoffmann R, Hakky S, Al-Sarireh A, Nowak MA, Shikora S, Ahmed AR, Ahmad SJ. · Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026)
Acute pancreatitis was exceedingly rare (0.22%).
Head-to-head dose comparisons showed no significant differences: 10 mg vs 5 mg (RR 0.78, 95% CI 0.29-2.09), 15 mg vs 5 mg (RR 0.70, 0.27-1.82), and 15 mg vs 10 mg (RR 1.13, 0.42-3.02); sensitivity analyses were concordant.
Most RoB 2.0 domains were low risk, with some concerns for missing data/selective reporting.
In plain English: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure.
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J; SURMOUNT-OSA Investigators. · N Engl J Med (2024)
Two 52-week phase-3 double-blind RCTs (SURMOUNT-OSA) in obese adults with moderate-to-severe OSA, off and on PAP therapy
Apnea-hypopnea index fell by an estimated 20.0 events/hour (trial 1) and 23.8 events/hour (trial 2) more than placebo
Also improved body weight, hypoxic burden, hsCRP, and systolic blood pressure
In plain English: Tirzepatide at all doses was noninferior and superior to semaglutide... Reductions in body weight were greater with tirzepatide than with semaglutide.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. · N Engl J Med (2021)
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
HbA1c fell -2.01% to -2.30% with tirzepatide vs -1.86% with semaglutide; all tirzepatide doses noninferior and superior
Greater weight loss with tirzepatide (treatment difference -1.9 to -5.5 kg vs semaglutide)